OKto enter 80A 3/10/05

In the claims:

For the convenience of the Examiner, all claims being examined, whether or not amended, are presented below.

Please cancel, without prejudice, claims 7 and 11-13

- 1. (Currently amended) Pharmaceutical composition containing a hydrophobically modified hedgehog protein and a biodegradable protein as a carrier, which pharmaceutical composition contains a hedgehog protein at a concentration of 0.1-100 mg/ml and which pharmaceutical composition is buffered in a range between pH 6 and 8 in a buffer comprising arginine or argininium ions at a concentration of 10-500 mmol/l, wherein said biodegradable protein binds the hedgehog protein and releases said protein in a delayed manner.
- 2. (Original) Pharmaceutical composition as claimed in claim 1, containing soluble collagen as a carrier.
- 3. (Original) Pharmaceutical composition as claimed in claim 1, containing insoluble, cross-linked collagen.
- 4. (Previously presented) Pharmaceutical composition as claimed in any of claims 1, 2, or 3, wherein said composition further contains a hyaluronic acid or alginate.

5-7. (Cancelled)

8. (Currently amended) Process for the production of a pharmaceutical composition, wherein a hydrophobically modified hedgehog protein is combined in a therapeutically effective amount with a biodegradable protein as a carrier, which pharmaceutical composition contains a hedgehog protein at a concentration of 0.1-100 mg/ml and which pharmaceutical composition is buffered in a range between pH 6 and 8 in a buffer comprising arginine or argininium ions at a concentration of 10-500 mmol/l, and wherein said biodegradable protein binds the hedgehog protein and releases said protein in a delayed manner.

9. (Withdrawn) Process for the delayed release of a hydrophobically modified hedgehog protein in the human body, wherein the said hedgehog protein is applied locally in the human body in a pharmaceutical composition as claimed in claims 1-7.

10-13. (Cancelled)

- 14. (Currently amended) The pharmaceutical composition of claim 1 11, wherein said buffer comprises arginine chloride.
- 15. (Previously presented) The pharmaceutical composition of claim 14, wherein said buffer further comprises potassium phosphate.

Please add the following new claim:

16. (New) The pharmaceutical composition of claim 14, wherein said buffer comprises 300 mmol/l arginine chloride.